Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN, Aranesp, ENBREL, Neulasta, and NEUPOGEN. The company operates in hematology, oncology, inflammation, metabolic, and bone disorder sectors.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 |
|---|---|---|
| Total Revenues | $2,713 | $7,641 |
| Net Income | $236 | $1,674 |
| Diluted EPS | $0.18 | $1.28 |
| Operating Cash Flow (9mo) | $2,587 | |
| Cash & Marketable Securities | $3,838 (as of Sep 30, 2004) | |
| Total Debt | $3,104 (includes $2.9B Convertible Notes) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 23% for the quarter and 27% for the nine-month period compared to 2003. Product sales rose 23% (quarter) and 28% (nine months), driven by demand for Aranesp, ENBREL, and Neulasta.
- Profitability Decline: Net income for the quarter dropped 61% to $236 million from $612 million in the prior year. This was primarily due to a $554 million non-cash write-off of acquired in-process research and development (IPR&D) related to the Tularik Inc. acquisition.
- Expense Increases:
- Cost of sales increased 31% (quarter) due to higher volumes and product mix.
- R&D expenses increased 23% (quarter) due to staff additions from Tularik and higher clinical activity.
- SG&A expenses increased 22% (quarter) due to marketing costs and incentive compensation.
- Effective Tax Rate: The effective tax rate for the quarter was 53.7% (vs. 29.3% in 2003), significantly elevated by the non-deductible IPR&D write-off. Excluding this item, the rate would have been 25.7%.
Guidance, Outlook, and Risks
- Reimbursement Risks (MMA): The Medicare Modernization Act (MMA) is expected to negatively impact 2005 reimbursement rates for key products (Aranesp, Neulasta, NEUPOGEN, EPOGEN). Changes include a shift from Average Wholesale Price (AWP) to Average Sales Price (ASP) methodologies and reduced rates for dialysis drugs.
- Supply Constraints: ENBREL sales may be constrained by manufacturing capacity. The company relies on third-party manufacturers (Boehringer Ingelheim, Genentech) and its own Rhode Island facility. Supply interruptions could materially affect results.
- Patent Expirations: Key European patents for erythropoietin and G-CSF are expiring in late 2004 and 2006, potentially exposing the company to biosimilar competition in Europe.
- Capital Allocation: The company repurchased $3.05 billion of common stock in the first nine months of 2004. Approximately $1.99 billion remains available under the current authorization. Capital expenditures for 2004 are estimated at $1.3 billion to $1.5 billion.
- Legal Proceedings: The company faces ongoing litigation regarding Average Wholesale Price (AWP) reporting and patent disputes (e.g., Transkaryotic Therapies). Management does not believe pending matters will have a material adverse effect on annual statements, though quarterly impacts are possible.
Investor Verification Checklist
- Tularik Acquisition Impact: Verify the integration progress of Tularik and the realization of anticipated synergies, given the $554 million immediate expense.
- Reimbursement Rate Changes: Monitor CMS final rules for 2005 ASP calculations and the specific impact on Aranesp and Neulasta pricing in the physician clinic and hospital outpatient settings.
- ENBREL Supply Chain: Confirm the status of the new Rhode Island manufacturing facility and the Genentech supply agreement to ensure no shortages occur during peak demand.
- Convertible Notes: Review the terms of the $2.9 billion Convertible Notes, which are classified as current liabilities due to potential put dates starting March 1, 2005.
- Stock Repurchase Program: Track the remaining $1.99 billion authorization and the company's ability to continue buybacks amidst capital expenditure needs and potential debt refinancing.